Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

With Actavis-Allergan On Track To Close Soon, Saunders Talks Integration

This article was originally published in The Pink Sheet Daily

Executive Summary

Brent Saunders, who will lead the new Allergan once the merger with Actavis closes, is ready to begin the integration, with an eye toward achieving 80% of the expected $2.3 billion in cost savings 12 months after close.

You may also be interested in...



Biden Infrastructure Plan Offers Biopharma R&D Carrot, Tax Stick

Tens of billions would go to fund R&D, including Phase I and Phase II development of vaccines. But the plan would also crack down on inversions and offshoring.

Actavis Puts Greater Emphasis On Branded Rx By Taking Allergan Name

The growing spec pharma has seen a 300% increase in its branded portfolio revenues since the acquisition of Forest and Warner Chilcott and is honoring the new direction by taking on the name of its most recent acquisition.

Actavis’ Big Bet On Diversified Hybrid Model Reflects Industry Trends

Actavis’ proposal to buy Forest Labs for $25 billion in stock and cash was driven by consolidating customers and fierce competition in traditional Western markets. Different pressures, namely the tough-to-manage patent cliff, as well as leadership succession issues and investor unrest, drove Forest into the arms of a suitor.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

PS078252

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel